Arcutis Biotherapeutics Inc
NASDAQ:ARQT

  • LAST PRICE
    9.2000
  • TODAY'S CHANGE (%)
    0.0800 (0.8772%)
  • Bid / Lots
    9.1100/ 2
  • Ask / Lots
    9.2000/ 1
  • Open / Previous Close
    9.1000 / 9.1200
  • Day Range
    8.5130
    9.2999
  • 52 Week Range
    1.7600
    13.1700
  • Volume
    3,450,543

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ARQT
Arcutis Biotherapeutics Inc
1.1B
-3.2x
---
ABCL
Abcellera Biologics Inc
1.1B
-7.2x
---
IMTX
Immatics NV
1.1B
-10.3x
---
NRIX
Nurix Therapeutics Inc
983.8M
-6.3x
---
CVAC
CureVac NV
782.8M
-2.7x
---
PRTA
Prothena Corporation PLC
1.2B
-6.9x
---
As of 2024-05-19

Company Information

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Contact Information

Headquarters
3027 Townsgate Road, Suite 300WESTLAKE VILLAGE, CA, United States 91361
Phone
805-418-5006
Fax
302-531-3150

Executives

Independent Chairman of the Board
Patrick Heron
President, Chief Executive Officer, Director
Todd Watanabe
Co-Founder, Senior Vice President, Chief Technology Officer
David Osborne
Chief Financial Officer
David Topper
Chief Human Resource Officer, Senior Vice President
Todd Tucker

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.1B
Revenue (TTM)
$106.4M
Shares Outstanding
115.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.19
EPS
$-2.91
Book Value
$0.92
P/E Ratio
-3.2x
Price/Sales (TTM)
10.0
Price/Cash Flow (TTM)
---
Operating Margin
-184.65%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.